|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-5-17
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To examine the efficacy and general safety of rivoglitazone, a novel thiazolidinedione, as a treatment for type 2 diabetes in a dose-ranging study over a period of up to 6 months.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1473-4877
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1321-31
|
|
pubmed:meshHeading |
pubmed-meshheading:20370378-Adolescent,
pubmed-meshheading:20370378-Adult,
pubmed-meshheading:20370378-Aged,
pubmed-meshheading:20370378-Diabetes Mellitus, Type 2,
pubmed-meshheading:20370378-Female,
pubmed-meshheading:20370378-Hemoglobin A, Glycosylated,
pubmed-meshheading:20370378-Humans,
pubmed-meshheading:20370378-Hypoglycemic Agents,
pubmed-meshheading:20370378-Male,
pubmed-meshheading:20370378-Middle Aged,
pubmed-meshheading:20370378-Placebos,
pubmed-meshheading:20370378-Thiazolidinediones,
pubmed-meshheading:20370378-Treatment Outcome,
pubmed-meshheading:20370378-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.
|
|
pubmed:affiliation |
Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA. ktruitt@dsi.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
